| Literature DB >> 35812021 |
Sarah E Minnis-Lyons1, Zara Aiken1, Shien Chow2, Shahida Din3.
Abstract
A frequent dilemma faced in the inflammatory bowel disease (IBD) clinic is how to best treat a patient with a previous cancer diagnosis. The changing demographics of our patient population will make this quandary more common. Previous guidance has emphasised the importance of lengthy postcancer drug holidays and cautious use of IBD therapies. However, accumulating evidence suggests this approach may be unnecessarily conservative. This review considers recent evidence on the safety of IBD drugs, cancer and recurrent cancer risk in patients with IBD and provides a framework for shared decision making involving patient, gastroenterologist and oncologist. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: adverse drug reactions; cancer; clinical decision making; inflammatory bowel disease
Year: 2022 PMID: 35812021 PMCID: PMC9234723 DOI: 10.1136/flgastro-2022-102187
Source DB: PubMed Journal: Frontline Gastroenterol ISSN: 2041-4137